Evidence map›Paper›PMID 39516658›Full record

ArticleOncogene2025

Targeting DDX3X eliminates leukemia stem cells in chronic myeloid leukemia by blocking NT5DC2 mRNA translation.

Chen Duan, Xiaoying Lin, Waiyi Zou, Qi He, Fen Wei, Jingxuan Pan, Chang Liu, Yanli Jin

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. RMzyme: regulations of RNA-modifying enzymes in humans.Signal transduction and targeted therapy · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chen Duan *State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Xiaoying Lin *State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Waiyi Zou *Department of Hematology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Qi He *State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Fen WeiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China.
Jingxuan PanState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China. panjx2@mail.sysu.edu.cn.
Chang LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. changliu@jnu.edu.cn.
Yanli JinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University, Guangzhou, China. yanlijin2014@jnu.edu.cn.ORCID http://orcid.org/0000-0001-7569-5546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) are highly effective in the treatment of patients with chronic myeloid leukemia (CML), but fail to eliminate leukemia stem cells (LSCs), which can lead to disease relapse or progression. It is urgently need to identify the regulators specifically driving LSCs. In this study, we identified DEAD-box helicase 3 X-linked (DDX3X), a ubiquitously expressed RNA helicase, as a critical regulator for CML LSCs by using patient samples and BCR-ABL-driven CML mouse model. We found that DDX3X enhanced the survival, serially plating and long-term engraftment abilities of human primary CML CD34

Indexed as

DEAD-box RNA HelicasesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveNeoplastic Stem CellsProtein BiosynthesisAnimalsCell Line, TumorHumansMiceRNA, MessengerXenograft Model Antitumor AssaysDDX3X protein, humanDEAD-box RNA HelicasesRNA, Messenger

Identifiers

PMID39516658

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.